Precigen Inc

Precigen Inc. tops Q1 2026 expectations with $21.6M in PAPZIMEOS™ revenue, a 145% jump, and a clear path to cash‑flow break‑even, driving investor confidence.

Precigen’s biotech breakthroughs in gene and cell therapy face fierce market volatility, with a negative P/E and fluctuating stock—investors weigh science versus profitability.

Precigen’s breakthrough gene‑cell therapies target oncology, autoimmune disease and infections, driving its biotech rise and attracting investors with a $1.36B market cap.

Precigen Inc. reports Q3 2025 earnings: $0.5 M net sales, FDA‑approved PAPZIMEOS for RRP, and outlook for revenue growth despite losses.

Precigen Inc.’s stock surged 144% in August 2025 after the FDA approved its pioneering therapy for a rare lung disease, boosting investor confidence and positioning the biopharmaceutical company for further growth.

The Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is gaining momentum, driven by expanding oncology applications and advancements in cell-based immunotherapy.

Precigen Inc. is a biopharmaceutical company pioneering gene and cell therapies to tackle complex health issues, revolutionizing the healthcare industry with innovative solutions.

Precigen, Inc. is a biopharmaceutical company pioneering the development of groundbreaking gene and cell therapies to address various health issues, including immuno-oncology, autoimmune disorders, and infections.